Investor Toolbox
Listen to Call
Recording not yet available.
Read Transcript
Transcript not yet available.
View Infographic
Infographic not yet available.
REGN Coverage
Event
Regeneron Pharmaceuticals Inc (REGN) Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Apr 23, 2026
Event
Regeneron Pharmaceuticals Inc (REGN) Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Apr 22, 2026
Event
Regeneron Pharmaceuticals Inc (REGN) Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
Apr 21, 2026
Transcript
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Transcript
Feb 2, 2026
Transcript
Regeneron Pharmaceuticals Inc (REGN) Q2 2025 Earnings Call Transcript
Jan 22, 2026
Transcript
Regeneron Pharmaceuticals Inc (REGN) Q3 2025 Earnings Call Transcript
Jan 22, 2026
News
Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls; revenue up 7%
May 4, 2023
Press Release
Earnings: Regeneron Pharmaceuticals (REGN) Q4 profit falls as revenues drop 31%
Feb 3, 2023